Gain Therapeutics, Inc.
Gain Therapeutics, Inc. (GANX) SEC Filings & 10-K Annual Reports
SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.
SEC EDGAR · data.sec.gov · CIK 0001819411 · GANX · NASDAQ · as of Jun 9, 2026
Filing snapshot
Source: SEC EDGAR (data.sec.gov) · CIK 0001819411 · Updated hourly · Not investment advice
Latest Annual Report
Latest Key Filings
Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.
SEC Filing History
About SEC Filings & 10-K Annual Reports
Gain Therapeutics, Inc. (NASDAQ: GANX) has submitted 224 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001819411, all filings are publicly accessible via the EDGAR database at no cost.
The annual 10-K report is Gain Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Gain Therapeutics, Inc. 10-K was filed on 2026-03-26 for fiscal year ending 2026. Historical GANX 10-K annual reports are available from 2020 through 2026.
Investors researching Gain Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.
Frequently Asked Questions
GANX SEC Filings · 8 questionsGain Therapeutics, Inc. (GANX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 224 filings and access original documents at no cost. Gain Therapeutics, Inc.'s CIK is 0001819411.